ADMS - Adamas Pharmaceuticals stock under pressure on $55M equity raise
Adamas Pharmaceuticals (ADMS) -7% premarket on pricing public offering of 12.5M common shares at $4.40/share, for gross proceeds of $55M.Underwriters' over-allotment is an additional 1.875M shares.Offering is expected to close on March 1.
For further details see:
Adamas Pharmaceuticals stock under pressure on $55M equity raise